Wed. 6 Mar 2024, 7:13am ET
Benzinga
Earnings, News
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.10) by 60 percent. This is a 33.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $231.00 thousand which missed the analyst consensus estimate of $20.47 million by 98.87 percent. This is a 97.91 percent decrease over sales of $11.03 million the same period last year.